Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of an adsorbed acellular DTaP (three-component) combined vaccine in 2-month-old infants
CTR20252023Phase 3Active
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adsorbed acellular DTaP combined vaccine, sponsored by Changchun Baimu Biotechnology. Started Jun 2025; status: active.
02
Drugs
adsorbed acellular DTaP combined vaccine
Beyond the preview
Go deeper on CTR20252023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252023.